免疫检查点抑制剂
ICIs是癌症治疗中常用的免疫疗法。T细胞上的免疫检查点蛋白与邻近细胞上的伴侣蛋白结合，使T细胞失活。2一些癌细胞表达伴侣蛋白，使T细胞失活，逃避免疫反应。ICIs抑制免疫检查点蛋白及其伴侣蛋白的结合，以防止T细胞失活。2
ALK抑制剂
MEK抑制剂
图一。一名患有转移性皮肤黑色素瘤的61岁男性主诉双眼视力下降。全身治疗包括BRAF抑制剂encorafenib和MEK抑制剂binimetinib。右眼视力保持在20/20，左眼视力保持在20/20-2。右眼(A)和左眼(B)的光学相干断层扫描(OCT)显示了黄斑视网膜下液的长条，也称为“分裂”配置。全身用药没有停用。当患者1个月后再次就诊时，视网膜下积液已自行消退。图片由马里兰州Kapil Mishra提供。
BRAF抑制剂
EGFR抑制剂
结论
参考文献
1. Liu CY, Francis JH, Abramson DH. Ocular side effects of systemically administered chemotherapy. UpToDate. May 8, 2024. Accessed August 21, 2024. https://www.uptodate.com
2. Abdou Y, Pandey M, Sarma M, Shah S, Baron J, Ernstoff MS. Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol. 2020;86(9):1690-1702. doi:10.1111/bcp.14316
3. Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021;105(9):1263-1271. doi:10.1136/bjophthalmol-2020-316970
4. Hou YL, Wang DY, Hu JX, et al. Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis. Ocul Immunol Inflamm. 2022;30(6):1449-1459. doi:10.1080/09273948.2021.1890133
5. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063-1078. doi:10.1097/IAE.0000000000002181
6. Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor–associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2021;29(1):203-211. doi:10.1080/09273948.2020.1781902
7. Vitiello L, Lixi F, Coco G, Giannaccare G. Ocular surface side effects of novel anticancer drugs. Cancers. 2024;16(2):344. doi:10.3390/cancers16020344
8. Gilbard JP. The diagnosis and management of dry eyes. Otolaryngol Clin North Am. 2005;38(5):871-885. doi:10.1016/j.otc.2005.03.012
9. Francis JH, Jaben K, Santomasso BD, et al. Immune checkpoint inhibitor–associated optic neuritis. Ophthalmology. 2020;127(11):1585-1589. doi:10.1016/j.ophtha.2020.05.003
10. Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non–small cell lung cancer (NSCLC). Mol Cancer. 2018;17:52. doi:10.1186/s12943-018-0810-4
11. Miyanaga A, Shimizu K, Noro R, et al. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small cell lung cancer harbored coexisting EGFR mutation. BMC Cancer. 2013;13(1):262. doi:10.1186/1471-2407-13-262
12. Chelala E, Hoyek S, Arej N, et al. Ocular and orbital side effects of ALK inhibitors: a review article. Future Oncol Lond Engl. 2019;15(16):1939-1945. doi:10.2217/fon-2018-0608
13. O’Bryant CL, Wenger SD, Kim M, Thompson LA. Crizotinib: a new treatment option for ALK-positive non–small cell lung cancer. Ann Pharmacother. 2013;47(2):189-197. doi:10.1345/aph.1R002
14. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non–small cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011-1019. doi:10.1016/S1470-2045(12)70344-3
15. Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618. doi:10.3390/cancers11101618
16. Han J, Chen J, Zhou H, Hao L, Wang Q. Ocular toxicities of MEK inhibitors in patients with cancer: a systematic review and meta-analysis. Oncology (Williston Park). 2023;37(3):130-141. doi:10.46883/2023.25920987
17. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122-136. doi:10.1177/1758834014566428
18. Gavric AU, Ocvirk J, Mekjavic PJ. Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib. Radiol Oncol. 2018;52(2):213-219. doi:10.2478/raon-2018-0002
19. Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831-837.e2. doi:10.1016/j.ajo.2014.07.003
20. Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3):e000491. doi:10.1136/esmoopen-2019-000491
21. Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chem. 2020;99:103811. doi:10.1016/j.bioorg.2020.103811
22. Höllhumer R, Moloney G, Jacob K. Corneal edema with a systemic epidermal growth factor receptor inhibitor. Can J Ophthalmol. 2017;52(3):e96-e97. doi:10.1016/j.jcjo.2016.11.018
23. Parrozzani R, Lombardi G, Midena E, et al. Ocular side effects of EGFR inhibitor ABT-414 in recurrent glioblastoma: a long-term safety study. Front Oncol. 2020;10:593461. doi:10.3389/fonc.2020.593461
24. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs. 2007;30(4):S10. doi:10.1097/01.NCC.0000281759.23823.82
